Black Rock Inc. Portage Biotech Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Portage Biotech Inc. stock. As of the latest transaction made, Black Rock Inc. holds 31,273 shares of PRTG stock, worth $15,011. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,273

Previous 35,240 11.26%

Holding current value

$15,011

Previous $64,000 73.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.41 - $1.89 $1,626 - $7,497	-3,967 Reduced 11.26%	31,273 $17,000
Q4 2023 Feb 13, 2024	BUY	$1.09 - $2.65 $3,398 - $8,262	3,118 Added 9.71%	35,240 $64,000
Q3 2023 Nov 13, 2023	SELL	$2.09 - $3.68 $2,062 - $3,632	-987 Reduced 2.98%	32,122 $67,000
Q2 2023 Aug 11, 2023	BUY	$2.73 - $3.87 $4,832 - $6,849	1,770 Added 5.65%	33,109 $115,000
Q1 2023 May 12, 2023	BUY	$2.6 - $7.2 $1,950 - $5,400	750 Added 2.45%	31,339 $96,000

Q4 2022 Feb 13, 2023	BUY	$4.42 - $7.44 $7,275 - $12,246	1,646 Added 5.69%	30,589 $161,000
Q3 2022 Nov 14, 2022	BUY	$6.81 - $10.12 $56,999 - $84,704	8,370 Added 40.68%	28,943 $198,000
Q2 2022 Aug 12, 2022	SELL	$5.16 - $11.95 $1.07 Million - $2.48 Million	-207,422 Reduced 90.98%	20,573 $144,000
Q1 2022 May 12, 2022	BUY	$6.57 - $12.0 $45,924 - $83,880	6,990 Added 3.16%	227,995 $1.5 Million
Q4 2021 Feb 10, 2022	BUY	$10.73 - $23.74 $84,573 - $187,118	7,882 Added 3.7%	221,005 $2.37 Million
Q3 2021 Nov 09, 2021	BUY	$13.65 - $22.4 $479,060 - $786,150	35,096 Added 19.71%	213,123 $4.33 Million
Q2 2021 Aug 11, 2021	BUY	$20.96 - $42.81 $3.73 Million - $7.62 Million	178,027 New	178,027 $3.73 Million

Others Institutions Holding PRTG

# of Institutions

Shares Held

2.16M

Call Options Held

Put Options Held

View Full List

About PORTAGE BIOTECH INC.

Ticker PRTG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,943,700
Market Cap $8.13M
Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a smal...

More about PRTG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account